NATCO Pharma gains 12% after receiving CDSCO approval for Semaglutide in India
News by Aliceblue News Desk
16 Feb 2026
Introduction
Leading pharmaceutical company received CDSCO approval for Semaglutide Injection in India and will launch the product in March 2026 for type 2 diabetes treatment.
Also Read: POWERGRID acquires Bellary-Davanagere transmission project for ₹13.2 Cr
Share price movement of NATCO Pharma
On February 16, 2026, Natco Pharma Ltd opened at ₹825.05, up 0.36% from its previous close of ₹822.10. The stock reached a high of ₹920.35 (11.95%) and a low of ₹825.05. By 10:43 AM, it traded at ₹915.60, an 11.37% increase, with a market cap of ₹16,399.30 crore.
NATCO Gets Semaglutide Approval
NATCO Pharma Limited received approval from the Central Drugs Standard Control Organisation for Semaglutide in India. The approval allows manufacture and marketing of generic Semaglutide Injection in India market.
NATCO Pharma Limited will launch Semaglutide Injection in March 2026. The drug is indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus.
Stock performance of NATCO Pharma for period of 1 week, 6 months, and 1 year
Natco Pharma Ltd declined 2.57% over the past week and fell 7.31% in six months. The stock dropped 6.72% over the past one year.
Also Read: Zensar wins $210M deal with top financial giant; details here
Shareholding pattern of NATCO Pharma
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 50% | 50% | 50% |
| FII | 15.20% | 14.10% | 15.50% |
| DII | 5.40% | 5.90% | 5.80% |
| Public | 30.00% | 31% | 29% |
About NATCO Pharma
Natco Pharma Ltd (NSE: NATCOPHARM) is a vertically integrated pharmaceutical company engaged in research, development, manufacturing and marketing of formulations, APIs and contract manufacturing services.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Natco Pharma Ltd share price rising today?
A: NATCO Pharma receives CDSCO approval for Semaglutide Injection in India; launch scheduled in March 2026 for type 2 diabetes treatment.
Q: What is Natco Pharma Ltd’s main business focus?
A: Natco Pharma Ltd develops, manufactures and markets formulations, APIs and provides contract manufacturing across niche therapeutic areas.
Q: What are the 52-week high and low of Natco Pharma Ltd stock?
A: Natco Pharma Ltd 52-week high is Rs.1,059.60 and 52-week low is Rs.660.05 on NS
News Author
Aliceblue News Desk
